Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) and Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Profitability
This table compares Jaguar Animal Health and Aldeyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -169.04% | -1,194.94% | -110.50% |
| Aldeyra Therapeutics | N/A | -57.34% | -36.33% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Jaguar Animal Health and Aldeyra Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
| Aldeyra Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Institutional & Insider Ownership
12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 2.1% of Jaguar Animal Health shares are owned by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Jaguar Animal Health has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
Valuation & Earnings
This table compares Jaguar Animal Health and Aldeyra Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jaguar Animal Health | $11.51 million | 0.11 | -$53.43 million | ($1,162.24) | 0.00 |
| Aldeyra Therapeutics | N/A | N/A | -$33.85 million | ($0.46) | -3.46 |
Aldeyra Therapeutics has lower revenue, but higher earnings than Jaguar Animal Health. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Aldeyra Therapeutics beats Jaguar Animal Health on 11 of the 13 factors compared between the two stocks.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
